8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Apr 10, 2026·SEC
Bruker Corporation(BRKR)Earnings, Financials & Key Ratios
BRKR•NASDAQ
Price updated Jun 17, 2026
AboutBruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.Show more
- Revenue$3.44B+2.1%
- EBITDA$456M+4.4%
- Net Income-$9M-107.6%
- EPS (Diluted)-0.15-119.7%
- Gross Margin45.91%-6.3%
- EBITDA Margin13.28%+2.3%
- Operating Margin6.87%-8.7%
- Net Margin-0.25%-107.5%
- ROE-0.4%-105.7%
BRKR Key Insights
Bruker Corporation (BRKR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Strong 5Y sales CAGR of 11.6%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BRKR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BRKR Price & Volume
Bruker Corporation (BRKR) stock price & volume — 10-year historical chart
Loading chart...
BRKR Growth Metrics
Bruker Corporation (BRKR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.79%
5 Years11.57%
3 Years10.74%
TTM0.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-114.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-145.98%
Return on Capital
10 Years13.53%
5 Years11.9%
3 Years8.96%
Last Year4.97%
BRKR Recent Earnings
Bruker Corporation (BRKR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.31+34.8%
$0.23
Rev
$823M+3.5%
$796M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.59-9.2%
$0.65
Rev
$977M+1.6%
$962M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.60+81.8%
$0.33
Rev
$861M-10.8%
$965M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.32-3.0%
$0.33
Rev
$797M-1.6%
$810M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.31vs $0.23+34.8% | $823Mvs $796M+3.5% |
| Q1 2026 | Feb 12, 2026 | $0.59vs $0.65-9.2% | $977Mvs $962M+1.6% |
| Q4 2025 | Nov 3, 2025 | $0.60vs $0.33+81.8% | $861Mvs $965M-10.8% |
| Q3 2025 | Aug 4, 2025 | $0.32vs $0.33-3.0% | $797Mvs $810M-1.6% |
Based on last 12 quarters of dataView full earnings history →
BRKR Peer Comparison
Bruker Corporation (BRKR) competitors in Imaging, radiation, and oncology devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 WAT | 23.27B | 357.00 | 33.18 | 6.99% | 11.91% | 8.04% | 0.55 | |
 TRMB | 11.58B | 48.87 | 27.93 | -2.61% | 12.37% | 7.95% | 0.24 | |
 FTV | 18.68B | 60.68 | 34.87 | -17.48% | 11.48% | 7.38% | 0.50 | |
 A | 35.12B | 124.37 | 27.21 | 6.73% | 19.55% | 20.84% | 0.50 | |
 TMO | 171.57B | 461.69 | 26.03 | 3.91% | 15.18% | 13.23% | 0.76 | |
 MTD | 22.83B | 1129.53 | 26.79 | 3.98% | 21.4% | |||
 ROP | 33.96B | 329.97 | 23.24 | 12.26% | 21.12% | 8.75% | 0.47 | |
 DHR | 125.88B | 177.85 | 35.29 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BRKR vs Peers
Bruker Corporation (BRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BRKR Income Statement
Bruker Corporation (BRKR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.77B | 1.9B | 2.07B | 1.99B | 2.42B | 2.53B | 2.96B | 3.37B | 3.44B | 3.46B |
Revenue Growth % | 9.59% | 7.34% | 9.34% | -4.11% | 21.66% | 4.67% | 17.14% | 13.56% | 2.08% | 0.36% |
Cost of Goods Sold | 952.9M | 995.6M | 1.08B | 1.05B | 1.21B | 1.23B | 1.45B | 1.72B | 1.86B | 1.89B |
COGS % of Revenue | 53.96% | 52.52% | 51.98% | 52.71% | 49.97% | 48.41% | 48.95% | 51% | 54.09% | - |
Gross Profit | 813M▲ 0% | 900M▲ 10.7% | 995.3M▲ 10.6% | 939.8M▼ 5.6% | 1.21B▲ 28.7% | 1.31B▲ 7.9% | 1.51B▲ 15.9% | 1.65B▲ 9.0% | 1.58B▼ 4.4% | 1.57B▲ 0% |
Gross Margin % | 46.04% | 47.48% | 48.02% | 47.29% | 50.03% | 51.59% | 51.05% | 49% | 45.91% | 45.29% |
Gross Profit Growth % | 9.49% | 10.7% | 10.59% | -5.58% | 28.71% | 7.94% | 15.9% | 9% | -4.35% | - |
Operating Expenses | 578.6M | 618.1M | 694.4M | 691.5M | 796.3M | 873M | 1.08B | 1.4B | 1.34B | 1.4B |
OpEx % of Revenue | 32.77% | 32.61% | 33.5% | 34.79% | 32.93% | 34.5% | 36.31% | 41.48% | 39.04% | - |
Selling, General & Admin | 415.9M | 444.7M | 504.8M | 477.8M | 562.3M | 607.4M | 729.4M | 893.8M | 946.5M | 963.2M |
SG&A % of Revenue | 23.55% | 23.46% | 24.36% | 24.04% | 23.26% | 24% | 24.6% | 26.55% | 27.54% | - |
Research & Development | 162.7M | 173.4M | 187.7M | 198M | 220.8M | 235.9M | 294.8M | 376.5M | 395.2M | 399.4M |
R&D % of Revenue | 9.21% | 9.15% | 9.06% | 9.96% | 9.13% | 9.32% | 9.94% | 11.18% | 11.5% | - |
Other Operating Expenses | 0 | 0 | 1.9M | 15.7M | 13.2M | 29.7M | 52.2M | 126.1M | 0 | 2M |
Operating Income | 214.7M▲ 0% | 262.4M▲ 22.2% | 300.9M▲ 14.7% | 248.3M▼ 17.5% | 413.3M▲ 66.5% | 432.7M▲ 4.7% | 436.9M▲ 1.0% | 253.1M▼ 42.1% | 236M▼ 6.8% | 168.9M▲ 0% |
Operating Margin % | 12.16% | 13.84% | 14.52% | 12.49% | 17.09% | 17.1% | 14.74% | 7.52% | 6.87% | 4.88% |
Operating Income Growth % | 21.16% | 22.22% | 14.67% | -17.48% | 66.45% | 4.69% | 0.97% | -42.07% | -6.76% | - |
EBITDA | 278.6M | 327.3M | 376.5M | 328.7M | 502.5M | 521.4M | 551.8M | 436.9M | 456.3M | 397.1M |
EBITDA Margin % | 15.78% | 17.27% | 18.17% | 16.54% | 20.78% | 20.6% | 18.61% | 12.98% | 13.28% | 11.48% |
EBITDA Growth % | 20.35% | 17.48% | 15.03% | -12.7% | 52.88% | 3.76% | 5.83% | -20.82% | 4.44% | -5.36% |
D&A (Non-Cash Add-back) | 63.9M | 64.9M | 75.6M | 80.4M | 89.2M | 88.7M | 114.9M | 183.8M | 220.3M | 228.2M |
EBIT | 235.6M | 275.2M | 296.4M | 240.2M | 407.9M | 430M | 560.6M | 254.8M | 82.3M | 67.2M |
Net Interest Income | -14.6M | -11.4M | -14.7M | -11.2M | -13.4M | -13.3M | -8.9M | -38.6M | -45.5M | -32.6M |
Interest Income | 800K | 1.2M | 1.3M | 3.2M | 900K | 2.8M | 7.5M | 9.3M | 14.8M | 2.9M |
Interest Expense | 15.4M | 12.6M | 16M | 14.4M | 14.3M | 16.1M | 16.4M | 47.9M | 60.3M | 58.9M |
Other Income/Expense | -21.7M | -17.7M | -20.5M | -22.5M | -19.7M | -17.8M | 109.3M | -47.9M | -215M | -170.9M |
Pretax Income | 197.8M▲ 0% | 244.7M▲ 23.7% | 280.4M▲ 14.6% | 225.8M▼ 19.5% | 393.6M▲ 74.3% | 414.9M▲ 5.4% | 546.2M▲ 31.6% | 205.2M▼ 62.4% | 21M▼ 89.8% | -2M▲ 0% |
Pretax Margin % | 11.2% | 12.91% | 13.53% | 11.36% | 16.28% | 16.39% | 18.42% | 6.1% | 0.61% | -0.06% |
Income Tax | 117.5M | 63.7M | 82.4M | 64.4M | 113M | 116.4M | 117.7M | 91.4M | 29.3M | 23.1M |
Effective Tax Rate % | 59.4% | 26.03% | 29.39% | 28.52% | 28.71% | 28.05% | 21.55% | 44.54% | 139.52% | -1155% |
Net Income | 78.6M▲ 0% | 179.7M▲ 128.6% | 197.2M▲ 9.7% | 157.8M▼ 20.0% | 277.1M▲ 75.6% | 296.6M▲ 7.0% | 427.2M▲ 44.0% | 113.1M▼ 73.5% | -8.6M▼ 107.6% | -11.6M▲ 0% |
Net Margin % | 4.45% | 9.48% | 9.51% | 7.94% | 11.46% | 11.72% | 14.41% | 3.36% | -0.25% | -0.34% |
Net Income Growth % | -48.83% | 128.63% | 9.74% | -19.98% | 75.6% | 7.04% | 44.03% | -73.53% | -107.6% | -114.57% |
Net Income (Continuing) | 80.3M | 181M | 198M | 161.4M | 280.6M | 298.5M | 428.5M | 113.8M | -8.3M | -9.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 8.1M | 8.5M | 31.4M | 13.1M | 14.3M | 18M | 36.1M | 34M | 53.8M | 35.8M |
EPS (Diluted) | 0.49▲ 0% | 1.14▲ 132.7% | 1.26▲ 10.5% | 1.02▼ 19.0% | 1.81▲ 77.5% | 1.99▲ 9.9% | 2.90▲ 45.7% | 0.76▼ 73.8% | -0.15▼ 119.7% | -0.08▲ 0% |
EPS Growth % | -48.42% | 132.65% | 10.53% | -19.05% | 77.45% | 9.94% | 45.73% | -73.79% | -119.74% | -145.98% |
EPS (Basic) | 0.50 | 1.15 | 1.27 | 1.03 | 1.83 | 2.00 | 2.92 | 0.76 | -0.15 | - |
Diluted Shares Outstanding | 159.1M | 157.2M | 156.6M | 154.6M | 152.9M | 149.4M | 147.2M | 149.5M | 151.8M | 152.7M |
Basic Shares Outstanding | 158.1M | 156.2M | 155.2M | 153.4M | 151.4M | 148.6M | 146.4M | 149M | 151.8M | 152.2M |
Dividend Payout Ratio | 32.32% | 13.97% | 12.68% | 15.59% | 8.73% | 10.05% | 6.88% | 26.7% | - | - |
BRKR Balance Sheet
Bruker Corporation (BRKR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.36B | 1.3B | 1.8B | 1.93B | 2.47B | 2.11B | 2.16B | 2.05B | 2.21B | 2.1B |
Cash & Short-Term Investments | 439.2M | 322.4M | 684.9M | 731.8M | 1.17B | 645.5M | 488.3M | 183.4M | 298.8M | 133.4M |
Cash Only | 325M | 322.4M | 678.3M | 681.8M | 1.07B | 645.5M | 488.3M | 183.4M | 298.8M | 133.4M |
Short-Term Investments | 114.2M | 0 | 6.6M | 50M | 100M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 319.3M | 357.2M | 362.2M | 335.3M | 416.9M | 595.3M | 621.8M | 701.2M | 736M | 542.7M |
Days Sales Outstanding | 66 | 68.78 | 63.79 | 61.58 | 62.93 | 85.86 | 76.56 | 76.03 | 78.17 | 73.46 |
Inventory | 486.2M | 509.6M | 577.2M | 692.3M | 710.1M | 800.1M | 968.3M | 1.07B | 1.09B | 1.12B |
Days Inventory Outstanding | 186.23 | 186.83 | 195.56 | 241.19 | 214.51 | 238.4 | 243.54 | 227.01 | 214.94 | 223.33 |
Other Current Assets | 114.1M | 115.1M | 172M | 165.6M | 176.6M | 29M | 30.3M | 39.6M | 47.9M | 306M |
Total Non-Current Assets | 589.7M | 824.3M | 975.2M | 1.12B | 1.18B | 1.5B | 2.09B | 3.75B | 4.03B | 4.03B |
Property, Plant & Equipment | 266.5M | 270.6M | 371.7M | 462.9M | 466M | 538.2M | 691.4M | 814.8M | 910.6M | 719.6M |
Fixed Asset Turnover | 6.63x | 7.01x | 5.58x | 4.29x | 5.19x | 4.70x | 4.29x | 4.13x | 3.77x | 4.41x |
Goodwill | 169.8M | 275.7M | 293M | 320.4M | 339.5M | 457.6M | 582.6M | 1.51B | 1.55B | 0 |
Intangible Assets | 82.4M | 218.7M | 233.2M | 229.1M | 211.8M | 270.9M | 330.5M | 912.5M | 899.6M | 0 |
Long-Term Investments | -71M | -59.3M | 0 | 0 | 0 | 0 | 0 | 0 | 8.2M | 16.1M |
Other Non-Current Assets | 14M | 8.4M | 16.8M | 39.6M | 70.8M | 155.1M | 184M | 232.7M | 241.1M | 3.31B |
Total Assets | 1.95B▲ 0% | 2.13B▲ 9.2% | 2.77B▲ 30.2% | 3.05B▲ 10.0% | 3.65B▲ 19.7% | 3.61B▼ 1.0% | 4.25B▲ 17.7% | 5.81B▲ 36.6% | 6.24B▲ 7.5% | 6.13B▲ 0% |
Asset Turnover | 0.91x | 0.89x | 0.75x | 0.65x | 0.66x | 0.70x | 0.70x | 0.58x | 0.55x | 0.55x |
Asset Growth % | 7.48% | 9.24% | 30.2% | 10.01% | 19.71% | -1.05% | 17.67% | 36.63% | 7.49% | 23.49% |
Total Current Liabilities | 524.5M | 598M | 645.6M | 791.9M | 938.5M | 914.3M | 1.2B | 1.28B | 1.28B | 1.36B |
Accounts Payable | 90.8M | 104.5M | 118.4M | 134.6M | 147.4M | 178.4M | 202.7M | 234.1M | 215.9M | 269.1M |
Days Payables Outstanding | 34.78 | 38.31 | 40.12 | 46.89 | 44.53 | 53.16 | 50.98 | 49.77 | 42.39 | 44 |
Short-Term Debt | 0 | 18.5M | 500K | 2.2M | 112.4M | 18.7M | 121.2M | 32.5M | 51.8M | 8.4M |
Deferred Revenue (Current) | 111.7M | 124.4M | 240.5M | 307.2M | 335.9M | 370.2M | 400M | 438.2M | 441.3M | 1.4B |
Other Current Liabilities | 256.3M | 288.5M | 119.5M | 121.3M | 156.4M | 159.9M | 218.3M | 300.3M | 302.8M | 597.9M |
Current Ratio | 2.59x | 2.18x | 2.78x | 2.43x | 2.63x | 2.31x | 1.80x | 1.60x | 1.73x | 1.55x |
Quick Ratio | 1.66x | 1.33x | 1.89x | 1.56x | 1.88x | 1.44x | 0.99x | 0.77x | 0.87x | 0.72x |
Cash Conversion Cycle | 217.45 | 217.29 | 219.23 | 255.87 | 232.91 | 271.1 | 269.12 | 253.27 | 250.72 | 252.78 |
Total Non-Current Liabilities | 690.5M | 625.5M | 1.19B | 1.28B | 1.63B | 1.57B | 1.63B | 2.71B | 2.45B | 2.27B |
Long-Term Debt | 415.6M | 322.6M | 812.8M | 842.3M | 1.22B | 1.2B | 1.16B | 2.06B | 1.69B | 1.66B |
Capital Lease Obligations | 1.3M | 7.1M | 47M | 47M | 41.8M | 34.8M | 74.8M | 118.9M | 296.6M | 296.6M |
Deferred Tax Liabilities | 24.3M | 51.1M | 48.8M | 43.1M | 46M | 62.3M | 67.7M | 118.5M | 112.5M | 112.5M |
Other Non-Current Liabilities | 200.6M | 182.5M | 236.3M | 299.5M | 266.9M | 166.5M | 240.2M | 311M | 239.2M | 609.9M |
Total Liabilities | 1.22B | 1.22B | 1.83B | 2.07B | 2.57B | 2.48B | 2.84B | 3.99B | 3.73B | 3.63B |
Total Debt | 415.6M | 341.1M | 880.9M | 912.8M | 1.39B | 1.27B | 1.38B | 2.25B | 2.04B | 1.67B |
Net Debt | 90.6M | 18.7M | 202.6M | 231M | 325.7M | 624.9M | 891.3M | 2.06B | 1.74B | 1.54B |
Debt / Equity | 0.56x | 0.37x | 0.94x | 0.94x | 1.28x | 1.12x | 0.98x | 1.24x | 0.81x | 0.67x |
Debt / EBITDA | 1.49x | 1.04x | 2.34x | 2.78x | 2.77x | 2.44x | 2.50x | 5.14x | 4.48x | 4.21x |
Net Debt / EBITDA | 0.33x | 0.06x | 0.54x | 0.70x | 0.65x | 1.20x | 1.62x | 4.72x | 3.82x | 3.87x |
Interest Coverage | 15.30x | 21.84x | 18.53x | 16.68x | 28.52x | 26.71x | 34.18x | 5.32x | 1.36x | 1.14x |
Total Equity | 741.6M▲ 0% | 913.6M▲ 23.2% | 938.2M▲ 2.7% | 974.3M▲ 3.8% | 1.08B▲ 11.3% | 1.13B▲ 4.3% | 1.41B▲ 24.9% | 1.82B▲ 28.4% | 2.51B▲ 38.3% | 2.5B▲ 0% |
Equity Growth % | 5.97% | 23.19% | 2.69% | 3.85% | 11.34% | 4.33% | 24.87% | 28.44% | 38.29% | 111.04% |
Book Value per Share | 4.66 | 5.81 | 5.99 | 6.30 | 7.09 | 7.58 | 9.60 | 12.14 | 16.54 | 16.39 |
Total Shareholders' Equity | 733.5M | 905.1M | 906.8M | 961.2M | 1.07B | 1.11B | 1.38B | 1.78B | 2.46B | 2.47B |
Common Stock | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.8M | 1.8M | 0 |
Retained Earnings | 942M | 1.1B | 1.27B | 1.41B | 1.66B | 1.93B | 2.32B | 2.41B | 2.36B | 0 |
Treasury Stock | -401.2M | -401.5M | -543.8M | -667M | -820.3M | -1.08B | -1.24B | -1.24B | -1.24B | 0 |
Accumulated OCI | 27M | 17M | -25.5M | 3.7M | -8.2M | 14.8M | 6M | -103.5M | -79.5M | 0 |
Minority Interest | 8.1M | 8.5M | 31.4M | 13.1M | 14.3M | 18M | 36.1M | 34M | 53.8M | 35.8M |
BRKR Cash Flow Statement
Bruker Corporation (BRKR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 154.4M | 239.7M | 213.4M | 332.2M | 282.4M | 274.4M | 350.1M | 251.3M | 134.1M | 140.3M |
Operating CF Margin % | 8.74% | 12.65% | 10.3% | 16.71% | 11.68% | 10.84% | 11.81% | 7.46% | 3.9% | - |
Operating CF Growth % | 18.04% | 55.25% | -10.97% | 55.67% | -14.99% | -2.83% | 27.59% | -28.22% | -46.64% | -11846.88% |
Net Income | 80.3M | 181M | 198M | 161.4M | 280.6M | 298.5M | 427.2M | 113.8M | 29.2M | -11.6M |
Depreciation & Amortization | 63.9M | 64.9M | 75.6M | 80.5M | 89.1M | 88.7M | 114.9M | 183.8M | 220.3M | 228.2M |
Stock-Based Compensation | 11M | 11.3M | 9.6M | 16M | 17.2M | 27.7M | 24M | 25.3M | 0 | 0 |
Deferred Taxes | 28.2M | -15.1M | -5.4M | -22.5M | -5.8M | -14.8M | -24.4M | -63.8M | -104.5M | -81.8M |
Other Non-Cash Items | 11.6M | 39.8M | 10.1M | 27.2M | 26.5M | 18.4M | -103.8M | 70.4M | 133.7M | 224.8M |
Working Capital Changes | -40.6M | -42.2M | -74.5M | 69.6M | -125.2M | -144.1M | -87.8M | -78.2M | -144.6M | -221.5M |
Change in Receivables | -55.5M | -30.5M | -5M | 40.8M | -95.3M | -67.9M | -900K | -40.6M | 0 | 0 |
Change in Inventory | -6.6M | -35.5M | -60.2M | -91.6M | -67M | -137.9M | -125M | -69.8M | 0 | -47.2M |
Change in Payables | 33.7M | 6.2M | 15.9M | -2.4M | 61.8M | 33.3M | 23.1M | 20.8M | -86M | 11.2M |
Cash from Investing | -30.2M | -123.4M | -158.4M | -192.7M | -192.4M | -251.6M | -326M | -1.76B | -196.5M | -210.1M |
Capital Expenditures | -43.7M | -49.2M | -73M | -97.2M | -92M | -129.2M | -106.9M | -115.3M | -90.8M | -89M |
CapEx % of Revenue | 2.47% | 2.6% | 3.52% | 4.89% | 3.81% | 5.11% | 3.61% | 3.43% | 2.64% | 2.57% |
Acquisitions | -66.3M | -191.6M | -90M | -59.2M | -65M | -182.3M | -226.6M | -1.6B | -73.9M | -88.8M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 11.5M | 118.9M | 11M | 200K | 4.9M | 13.9M | 11.1M | 1.1M | -31.8M | -32.3M |
Cash from Financing | -159M | -112.4M | 300M | -161.6M | 318.7M | -415.3M | -193.4M | 1.23B | 135.1M | -18.6M |
Debt Issued (Net) | 3.1M | -93.5M | 467M | -8.3M | 489.7M | -110.7M | -21.5M | 875.9M | -491.3M | -640.4M |
Equity Issued (Net) | -152.2M | 9.4M | -131.4M | -119.9M | -146.3M | -263.1M | -142.8M | 403M | 659.7M | -5.5M |
Dividends Paid | -25.4M | -25.1M | -25M | -24.6M | -24.2M | -29.8M | -29.4M | -30.2M | -22.8M | -36.2M |
Share Repurchases | -152.2M | 0 | -142.3M | -123.2M | -153.3M | -263.1M | -152.3M | 0 | -10M | 0 |
Other Financing | 15.5M | -3.2M | -10.6M | -8.8M | -500K | -11.7M | 300K | -18.9M | -10.5M | 663.5M |
Net Change in Cash | -17M▲ 0% | -2.6M▲ 84.7% | 355.6M▲ 13776.9% | 3.6M▼ 99.0% | 386.2M▲ 10627.8% | -423M▼ 209.5% | -157.1M▲ 62.9% | -304.9M▼ 94.1% | 116.4M▲ 138.2% | -50.1M▲ 0% |
Free Cash Flow | 110.7M▲ 0% | 190.5M▲ 72.1% | 140.4M▼ 26.3% | 235M▲ 67.4% | 190.4M▼ 19.0% | 145.2M▼ 23.7% | 243.2M▲ 67.5% | 136M▼ 44.1% | 43.3M▼ 68.2% | 51.3M▲ 0% |
FCF Margin % | 6.27% | 10.05% | 6.77% | 11.82% | 7.87% | 5.74% | 8.2% | 4.04% | 1.26% | 1.48% |
FCF Growth % | 18.14% | 72.09% | -26.3% | 67.38% | -18.98% | -23.74% | 67.49% | -44.08% | -68.16% | -70.62% |
FCF per Share | 0.70 | 1.21 | 0.90 | 1.52 | 1.25 | 0.97 | 1.65 | 0.91 | 0.29 | 0.34 |
FCF Conversion (FCF/Net Income) | 1.96x | 1.33x | 1.08x | 2.11x | 1.02x | 0.93x | 0.82x | 2.22x | -15.59x | -4.42x |
Interest Paid | 15.2M | 11.7M | 16M | 28.7M | 19.6M | 24.3M | 33.7M | 54.6M | 0 | 14.7M |
Taxes Paid | 53.1M | 60.5M | 61.3M | 43M | 145.5M | 147.4M | 96.6M | 153.9M | 0 | 38.7M |
BRKR Key Ratios
Bruker Corporation (BRKR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 10.91% | 21.71% | 21.3% | 16.5% | 26.91% | 26.76% | 33.57% | 7.01% | -0.4% | -0.5% |
Return on Invested Capital (ROIC) | 20.11% | 22.31% | 21.77% | 15.88% | 23.7% | 20.49% | 16.14% | 6.14% | 4.35% | 3.03% |
Gross Margin | 46.04% | 47.48% | 48.02% | 47.29% | 50.03% | 51.59% | 51.05% | 49% | 45.91% | 45.29% |
Net Margin | 4.45% | 9.48% | 9.51% | 7.94% | 11.46% | 11.72% | 14.41% | 3.36% | -0.25% | -0.34% |
Debt / Equity | 0.56x | 0.37x | 0.94x | 0.94x | 1.28x | 1.12x | 0.98x | 1.24x | 0.81x | 0.67x |
Interest Coverage | 15.30x | 21.84x | 18.53x | 16.68x | 28.52x | 26.71x | 34.18x | 5.32x | 1.36x | 1.14x |
FCF Conversion | 1.96x | 1.33x | 1.08x | 2.11x | 1.02x | 0.93x | 0.82x | 2.22x | -15.59x | -4.42x |
Revenue Growth | 9.59% | 7.34% | 9.34% | -4.11% | 21.66% | 4.67% | 17.14% | 13.56% | 2.08% | 0.36% |
Related:BRKR Dividend History·BRKR Revenue History·BRKR Price History·BRKR P/E History·BRKR Financial Ratios·BRKR Institutional Holders
BRKR SEC Filings & Documents
Bruker Corporation (BRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)
BRKR Frequently Asked Questions
Bruker Corporation (BRKR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bruker Corporation (BRKR) reported $3.46B in revenue for fiscal year 2025. This represents a 5246% increase from $64.7M in 1999.
Bruker Corporation (BRKR) grew revenue by 2.1% over the past year. Growth has been modest.
Bruker Corporation (BRKR) reported a net loss of $11.6M for fiscal year 2025.
Dividend & Returns
Yes, Bruker Corporation (BRKR) pays a dividend with a yield of 0.27%. This makes it attractive for income-focused investors.
Bruker Corporation (BRKR) has a return on equity (ROE) of -0.4%. Negative ROE indicates the company is unprofitable.
Bruker Corporation (BRKR) generated $51.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.